ArticleiScience2026
Ultrasound-targeted microbubble destruction enhances RSL3-induced ferroptosis in anaplastic thyroid carcinoma.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with limited effective therapies. Ferroptosis, a form of programmed cell death, is closely associated with thyroid cancer prognosis and represents a potential therapeutic target. This study evaluated the antitumor effects of ultrasound-targeted microbubble (MB) destruction (UTMD)-mediated RAS-selective lethal 3 (RSL3) delivery to induce ferroptosis in ATC. MBs loaded with ferroptosis inducer RSL3 were synthesized and intravenously administered in a nude mouse ATC model, followed by localized ultrasound irradiation to enable targeted intratumoral drug release. RSL3-MBs exhibited uniform particle size, good biocompatibility, and excellent contrast performance. The combination of RSL3-MBs with UTMD significantly inhibited the growth of ATC without evident systemic toxicity. This strategy was shown to be more effective than the delivery methods involving either RSL3 solution or RSL3-MBs alone. These findings support UTMD-mediated RSL3 delivery as an effective approach to enhance ferroptosis-based therapy for ATC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.